BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
BridgeBio Pharma director Charles J. Homcy reported equity awards consisting of restricted stock units and stock options. He received 3,990 RSUs, each representing a contingent right to one share of common stock, and 5,277 stock options with an exercise price of $68.92 per share.
The RSUs and the shares underlying the options vest in full on June 22, 2027, conditioned on his continued service on the board of directors through that date. Following the RSU grant, Homcy directly holds 919,876 shares of BridgeBio common stock, plus 5,277 options expiring on June 21, 2036.
BridgeBio Pharma director Eric Aguiar received new equity awards. On June 22, 2026, he was granted 3,990 restricted stock units, each representing one share of common stock, and 5,277 stock options with an exercise price of $68.92 per share.
The RSUs and the shares underlying the stock options vest in full on June 22, 2027, as long as he continues serving on the board through that date. After these awards, he holds 10,579 shares of common stock directly, plus the 5,277 options expiring on June 21, 2036.
BridgeBio Pharma director Ronald J. Daniels reported equity awards as part of his compensation. He received 3,990 restricted stock units, each representing one share of common stock, granted at no cash cost. These RSUs vest in full on June 22, 2027, if he continues serving on the board until that date.
Daniels was also granted a stock option covering 5,277 shares of common stock at an exercise price of $68.92 per share, also vesting in full on June 22, 2027, subject to continued board service. Following the RSU grant, he directly holds 20,981 shares of BridgeBio common stock. The filing shows no open‑market buys or sells, only award-related acquisitions.
BridgeBio Pharma, Inc. director Ellis Andrea reported receiving new equity awards. On June 22, 2026, Ellis was granted 3,990 restricted stock units that vest in full on June 22, 2027, subject to continued board service. Each RSU represents one share of common stock.
Ellis was also granted a stock option covering 5,277 shares of common stock at an exercise price of $68.92 per share, expiring on June 21, 2036, with all option shares vesting on June 22, 2027. Following these awards, Ellis directly holds 22,579 shares of common stock.
BridgeBio Pharma director Fred Hassan reported new equity awards in the form of stock units and options. He received 3,990 restricted stock units, each representing one future share of common stock, bringing his direct common share holdings to 29,879 after the grant.
Hassan was also granted options covering 5,277 shares of common stock at an exercise price of $68.92 per share. Both the RSUs and the option shares vest in full on June 22, 2027, conditioned on his continued service on BridgeBio’s board of directors through that date. The stock options expire on June 21, 2036.
BridgeBio Pharma director James C. Momtazee reported new equity awards and an ownership reclassification. He received 3,990 restricted stock units that each convert into one share of common stock and vest in full on June 22, 2027, if he continues serving on the board.
He was also granted a stock option for 5,277 shares of common stock at an exercise price of $68.92 per share, vesting in full on June 22, 2027. After these awards, he holds 19,070 shares directly, while 80,000 shares are now reported as indirectly owned through the James C. Momtazee Revocable Trust, which were previously reported as directly owned.
BridgeBio Pharma director Frank McCormick reported new equity awards and updated his holdings. He received 3,990 restricted stock units, each representing one share of common stock, and a stock option covering 5,277 shares at an exercise price of $68.92 per share.
The RSUs and the option shares both vest in full on June 22, 2027, conditioned on his continued service on the board. After these awards, he holds 10,579 shares directly and 756,665 shares indirectly through the Francis P. McCormick Rev Trust.
The filing also corrects a previously reported transfer of 352,290 shares that did not occur and clarifies that 428,976 shares were transferred from his direct holdings to his trust account on June 3, 2026.
BridgeBio Pharma director Douglas A. Dachille reported routine equity awards and existing indirect holdings. He received 3,990 restricted stock units (RSUs) that vest in full on June 22, 2027, contingent on his continued service on the board. Each RSU represents one share of common stock, giving him 10,579 shares of common stock held directly after the award.
He also received a stock option for 5,277 shares of common stock with a $68.92 per-share exercise price, vesting in full on June 22, 2027, also tied to continued board service. Separately, 20,000 shares of common stock are held indirectly by The Dachille 2012-1 Family Trust for his children, with his spouse as trustee. Dachille disclaims beneficial ownership of those trust shares for Section 16 and other purposes.
BridgeBio Pharma director Ali J. Satvat reported equity awards rather than market trades. He received 3,990 restricted stock units (RSUs) that vest in full on June 22, 2027, conditioned on his continued service on the board. Each RSU represents a contingent right to receive one share of BridgeBio’s common stock.
Satvat was also granted a stock option covering 5,277 shares of common stock at an exercise price of $68.9200 per share, expiring on June 21, 2036. These option shares vest in full on June 22, 2027, subject to the same continued-service condition. Following the RSU grant, he directly holds 169,983 shares of common stock.
Randal Scott reported a proposed resale under Form 144. The notice lists a 10b5-1 sale of 10,000 shares of Common Stock on 05/15/2026 with proceeds shown as $671,456.00. The filing also lists 2,196 Restricted Stock Units dated 06/20/2026 that are identified as securities to be sold.
The filing names Morgan Stanley Smith Barney LLC as the broker/dealer. Transaction timing and mechanics reflect a 10b5-1 sale; further details about remaining holdings or post-transaction ownership are not included in the provided excerpt.